A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy

NCT03356587 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

32

Enrollment

OTHER

Sponsor class

Conditions

HNSCC
Head and Neck Neoplasms

Interventions

DRUG: Abemaciclib

Sponsor

Seoul National University Hospital